Advancing Viral Vector Gene Therapies With Strategic Manufacturing Partnerships

By Dr. Guodong Javier Jia, CEO, OBiO Tech

Viral vectors serve as vehicles to introduce foreign genetic material to the body and make up an essential component of gene therapies across a wide range of indications. Currently, there are four types of viral vectors used in gene therapy: adenovirus, adeno-associated vectors (AAV), lentivirus, and Y-retroviral. Each of which requires a complex manufacturing process. Due to the potential risks and costs associated with these processes, it is critical to align yourself with knowledgeable partners to mitigate risks and maintain a cost-effective budget.

If your biotech is new to navigating the inherent obstacles of viral vector manufacturing for clinical trials, consider how partnering with an experienced cell and gene therapy manufacturer can help you identify the best manufacturing and quality control approaches for your specific therapy. A knowledgeable CDMO can guide a drug product through each stage of its pipeline, help developers reap the benefits of cutting-edge facilities and experienced project management, and, most importantly, delivery therapies to patients faster.